Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy.
Endoscopic ultrasonography
Endoscopic ultrasound-guided fine-needle biopsy
Pancreatic cancer
Smad4 mutations
p53 mutation
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
22
02
2023
accepted:
28
07
2023
medline:
2
11
2023
pubmed:
19
8
2023
entrez:
18
8
2023
Statut:
ppublish
Résumé
This prospective cohort study evaluated the feasibility of using endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) samples for comprehensive mutational analysis of cancer-related genes using microtissues. Fifty patients with suspected pancreatic cancer presenting consecutively at the Kindai University Hospital between January 2018 and January 2019 were enrolled. Cancerous tissues from EUS-FNB were obtained from each tumor and subjected to histological examination and mutational analysis. The primary endpoint was the collection rate of EUS-FNB specimens suitable for comprehensive cancer panels using deep sequencing. Clinical history and genetic variations between the disease control and progressive disease groups of patients on chemotherapy were evaluated as secondary endpoints. The collection rate of EUS-FNB specimens suitable for comprehensive cancer panels using deep sequencing was 93.6%. The cancer panel was sequenced for 25 patients with pancreatic cancer treated initially with systemic chemotherapy. Mutation in p53 and Smad4 were positively and negatively associated, respectively, with disease control at the initial evaluation. The median time to progression in 15 patients with p53 and without Smad4 mutations was 182.0 days; whereas, it was 92.5 days in other 10 patients; this difference was significant (p = 0.020). Tissue samples from EUS-FNB were suitable for mutational analysis. Pancreatic cancers with p53 and without Smad4 mutations responded better to chemotherapy and had a better prognosis than those others.
Sections du résumé
BACKGROUND
BACKGROUND
This prospective cohort study evaluated the feasibility of using endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) samples for comprehensive mutational analysis of cancer-related genes using microtissues.
METHODS
METHODS
Fifty patients with suspected pancreatic cancer presenting consecutively at the Kindai University Hospital between January 2018 and January 2019 were enrolled. Cancerous tissues from EUS-FNB were obtained from each tumor and subjected to histological examination and mutational analysis. The primary endpoint was the collection rate of EUS-FNB specimens suitable for comprehensive cancer panels using deep sequencing. Clinical history and genetic variations between the disease control and progressive disease groups of patients on chemotherapy were evaluated as secondary endpoints.
RESULTS
RESULTS
The collection rate of EUS-FNB specimens suitable for comprehensive cancer panels using deep sequencing was 93.6%. The cancer panel was sequenced for 25 patients with pancreatic cancer treated initially with systemic chemotherapy. Mutation in p53 and Smad4 were positively and negatively associated, respectively, with disease control at the initial evaluation. The median time to progression in 15 patients with p53 and without Smad4 mutations was 182.0 days; whereas, it was 92.5 days in other 10 patients; this difference was significant (p = 0.020).
CONCLUSIONS
CONCLUSIONS
Tissue samples from EUS-FNB were suitable for mutational analysis. Pancreatic cancers with p53 and without Smad4 mutations responded better to chemotherapy and had a better prognosis than those others.
Identifiants
pubmed: 37596505
doi: 10.1007/s10147-023-02396-w
pii: 10.1007/s10147-023-02396-w
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
TP53 protein, human
0
SMAD4 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1511-1519Subventions
Organisme : JSPS KAKENHI
ID : 21K07184
Informations de copyright
© 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Références
DeWitt J, Devereaux B, Chriswell M et al (2004) Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 141:753–763
doi: 10.7326/0003-4819-141-10-200411160-00006
pubmed: 15545675
Vilmann P, Jacobsen GK, Henriksen FW et al (1992) Endoscopic ultrasonography with guided fine needle aspiration biopsy in pancreatic disease. Gastrointest Endosc 38:172–173
doi: 10.1016/S0016-5107(92)70385-X
pubmed: 1568614
Plougmann JI, Klausen P, Toxvaerd A et al (2020) DNA sequencing of cytopathologically inconclusive EUS-FNA from solid pancreatic lesions suspicious for malignancy confirms EUS diagnosis. Endosc Ultrasound 9:37–44
doi: 10.4103/eus.eus_36_19
pubmed: 31552911
Rodriguez SA, Impey SD, Pelz C et al (2016) RNA sequencing distinguishes benign from malignant pancreatic lesions sampled by EUS-guided FNA. Gastrointest Endosc 84:252–258
doi: 10.1016/j.gie.2016.01.042
pubmed: 26808815
Takano S, Fukasawa M, Shindo H et al (2021) Digital next-generation sequencing of cell-free DNA for pancreatic cancer. JGH Open 5:508–516
doi: 10.1002/jgh3.12530
pubmed: 33860102
pmcid: 8035455
Dianxu F, Shengdao Z, Tianquan H et al (2002) A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis. Pancreas 25:336–341
doi: 10.1097/00006676-200211000-00003
pubmed: 12409826
Hansel DE, Kern SE, Hruban RH (2003) Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet 4:237–256
doi: 10.1146/annurev.genom.4.070802.110341
pubmed: 14527303
Yamaguchi K, Okusaka T, Shimizu K et al (2017) Clinical practice guidelines for pancreatic cancer 2016 from the Japan pancreas society: a synopsis. Pancreas 46:595–604
doi: 10.1097/MPA.0000000000000816
pubmed: 28426492
Kamata K, Takenaka M, Omoto S et al (2018) Impact of avascular areas, as measured by contrast-enhanced harmonic EUS, on the accuracy of FNA for pancreatic adenocarcinoma. Gastrointest Endosc 87:158–163
doi: 10.1016/j.gie.2017.05.052
pubmed: 28619244
Hayashi A, Hong J, Iacobuzio-Donahue CA (2021) The pancreatic cancer genome revisited. Nat Rev Gastroenterol Hepatol 18:469–481
doi: 10.1038/s41575-021-00463-z
pubmed: 34089011
Dreyer SB, Jamieson NB, Evers L et al (2019) Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Chin Clin Oncol 8:16
doi: 10.21037/cco.2019.04.06
pubmed: 31070037
Izawa N, Morizane C, Takahashi H et al (2018) The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: efficient identification of cancer genome alterations in advanced pancreatic cancer. Ann Oncol 29:viii216–viii217
doi: 10.1093/annonc/mdy282.028
Kurahara H, Maemura K, Mataki Y et al (2016) Impact of p53 and PDGFR-β expression on metastasis and prognosis of patients with pancreatic cancer. World J Surg 40:1977–1984
doi: 10.1007/s00268-016-3477-2
pubmed: 26940582
Zhang SY, Ruggeri B, Agarwal P et al (1994) Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 118:150–154
pubmed: 8311654
DiGiuseppe JA, Hruban RH, Goodman SN et al (1994) Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 101:684–688
doi: 10.1093/ajcp/101.6.684
pubmed: 8209852
Yang G, Guan W, Cao Z et al (2021) Integrative genomic analysis of gemcitabine resistance in pancreatic cancer by patient-derived xenograft models. Clin Cancer Res 27:3383–3396
doi: 10.1158/1078-0432.CCR-19-3975
pubmed: 33674273
Williams AB, Schumacher B (2016) p53 in the DNA-damage-repair process. Cold Spring Harb Perspect Med 6:a026070
doi: 10.1101/cshperspect.a026070
pubmed: 27048304
pmcid: 4852800
Schaafsma E, Takacs EM, Kaur S et al (2022) Predicting clinical outcomes of cancer patients with a p53 deficiency gene signature. Sci Rep 12:1317
doi: 10.1038/s41598-022-05243-6
pubmed: 35079034
pmcid: 8789768
Bailey P, Chang DK, Nones K et al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:47–52
doi: 10.1038/nature16965
pubmed: 26909576
Wang F, Xia X, Yang C et al (2018) SMAD4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy. Clin Cancer Res 24:3176–3185
doi: 10.1158/1078-0432.CCR-17-3435
pubmed: 29602802
pmcid: 6345154
Yoon JG, Kim MH, Jang M et al (2021) Molecular characterization of biliary tract cancer predicts chemotherapy and programmed death 1/programmed death-ligand 1 blockade responses. Hepatology 74:1914–1931
doi: 10.1002/hep.31862
pubmed: 33884649
Yamada D, Kobayashi S, Wada H et al (2013) Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur J Cancer 49:1725–1740
doi: 10.1016/j.ejca.2012.12.002
pubmed: 23298711
Park JW, Seo MJ, Cho KS et al (2022) Smad 4 and p53 synergize in suppressing autochthonous intestinal cancer. Cancer Med 11:1925–1936
doi: 10.1002/cam4.4533
pubmed: 35274815
pmcid: 9089223
Kalo E, Buganim Y, Shapira KE et al (2007) Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II. Mol Cell Biol 27:8228–8242
doi: 10.1128/MCB.00374-07
pubmed: 17875924
pmcid: 2169171
Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15:178–196
doi: 10.1038/nrm3758
pubmed: 24556840
pmcid: 4240281
O’Reilly EM, Oh DY, Dhani N et al (2019) Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol 5:1431–1438
doi: 10.1001/jamaoncol.2019.1588
pubmed: 31318392
pmcid: 6647002